In one study on the clinical outcome of pembrolizumab versus chemotherapy in lung cancer patients, it was observed that the treatment outcomes appeared to be comparable irrespective of the presence of STK11, KEAP1, or KRAS mutations [113]. Here, KRAS is linked to lung carcinoma.